• Boston Scientific has agreed to acquire Penumbra for $14.5bn of which c$11bn will be in cash and new debt. BSX has sufficient headroom within its rating for this deal, allowing for some leniency from the agencies, so may not lead to a downgrade but will mean significant debt issuance. Currently, 2/3 of its bonds are in EUR but we see a cost advantage towards USD issuance for this takeover. BSX widened 4.5bps.
• Sanofi was said to have bid $3.4bn for Ocular Therapeutix. SANFP issued €5.5bn in 2025 and has €3bn due in 2026.
• Eli Lilly was also reported to be considering a $15bn bid for Abivax. This would only be ~0.4x leverage but would require issuance.
• In other M&A news, Novo Nordisk’s CEO expressed an interest in large takeover activity in a Bloomberg interview at the JPM Health conference. Novo recently lost out to Pfizer in the $10bn hunt for Metsera.

Find more articles and bullets on these widgets:
The German 5s30s curve has retraced around 60% of the early December flattening, keeping an underlying steepening theme intact. The curve is back above 100bps at 102.4bps, up just over 1bp on the session. Tomorrow’s Eurozone risk events will be key for the direction of the spread into year-end, with the front of the curve eyeing the ECB decision and press conference, and the mid/long-end cognisant of Germany’s 2026 issuance plan.
Figure 1: German 5s30s (Source: Bloomberg Finance L.P)

OEG6 117.5 ^, bought for 142 in 2k.